LymphoDrain
Financiado
LymphoDrain The definitive solution for chronic lymphedema
Lymphedema (LE) is a chronic disfunction of the lymphatic system causing fluid accumulation in the limbs, which affects more than 100 million patients worldwide. Its occurrence is closely related to cancer, being a very common sid...
Lymphedema (LE) is a chronic disfunction of the lymphatic system causing fluid accumulation in the limbs, which affects more than 100 million patients worldwide. Its occurrence is closely related to cancer, being a very common side effect of cancer therapies, but can also arise from genetic disorders or due to injury, trauma, venous disorders, obesity, immobility,
etc. Despite recent advances, at present there is no cure for LE which becomes a chronic disorder. The disease must be treated constantly by the patient, to avoid complications, with daily use of compression garments, physiotherapy and skin care. Thus, it creates a constant disability for the patient and, more importantly, it affects his/her ability to work and to live a
normal life. In Europe, the financial impact of LE is valued at around €832 million in health and social welfare bills, with an additional €2.3 billion used to treat infections secondary to LE, as well as an additional €4.4 billion in loss of earnings as a result of productive incapacity of the patients. In addition, the prevalence of chronic LE is expected to grow as the life
expectancy increases and the global population ages. There is an urgent need for innovative approaches to restore continuous lymph flow drainage in affected tissues, producing a definitive solution for LE. Lymphatica´s subcutaneous implant, LymphoDrain, consists of a draining catheter and a micro-pump externally controlled by a wearable device, and replaces the function of lymphatic vessels. It is implanted via a minimally invasive procedure, and results in the resolution of the physiological impairments caused by LE reducing pain, the risk of potential complications and the need for additional treatments. Lymphatica´s goal is to convert LymphoDrain in the first definitive solution for LE patients and a clear solution for reducing the impact of LE on both the healthcare system and the economy of each country.
ver más
Duración del proyecto: 41 meses
Fecha Inicio: 2019-08-07
Fecha Fin: 2023-01-31
Fecha Fin: 2023-01-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-01-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
LYMPHATICA MEDTECH SA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
597.03K€ |
Participante